<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We tried to treat 13 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, with alfacalcidol for their hematological improvement </plain></SENT>
<SENT sid="1" pm="."><plain>Eight of them had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 2 <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (M3, M4), 1 <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> and 2 primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were untreated except for 3 patients (PASA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M4) who had been treated with mepitiostane, <z:chebi fb="2" ids="8378">prednisolone</z:chebi> and BH.AC-<z:chebi fb="47" ids="16027,28971">AMP</z:chebi> regimen, respectively, prior to alfacalcidol therapy </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received alfacalcidol orally for at least one month </plain></SENT>
<SENT sid="4" pm="."><plain>The dosage of alfacalcidol ranged from 0.25 to 10 micrograms/day, and the medicine was administrated intermittently when the dosage exceeded 6 micrograms/day to prevent <z:hpo ids='HP_0003072'>hypercalcemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The therapeutic effectiveness of alfacalcidol was evaluated according to a criteria by Koeffler (<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Treat Rep 69: 1399, 1985) with minor modifications </plain></SENT>
<SENT sid="6" pm="."><plain>Three patients (PASA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) showed partial response, 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in T, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M4) minor response and rest of the patients did not respond </plain></SENT>
<SENT sid="7" pm="."><plain>The hematological improvement of 6 responders was transient (from 1 to 2 months), however, one patient (PASA) is still responding to alfacalcidol therapy (0.25 microgram/day) for over 12 months </plain></SENT>
<SENT sid="8" pm="."><plain>The dysplastic features of hemopoietic cells in the bone marrow showed no noticeable change during the hematological improvement in these responders, suggesting the improvement was obtained as a result of alteration in the proliferation or differentiation of neoplastic clone </plain></SENT>
<SENT sid="9" pm="."><plain>None of 13 patients developed <z:hpo ids='HP_0003072'>hypercalcemia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>One patient (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M4) became excitable on high dose alfacalcidol (10 micrograms/day) </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, alfacalcidol therapy is effective in some patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:hpo ids='HP_0001909'>leukemias</z:hpo> and appears worthy especially in the clinical state in which chemotherapy is not indicated </plain></SENT>
</text></document>